1 2 3 4 5 6 7 8 9 10 11 12
÷èòàòü äàëåå ... for relapse-free survival in patients with follicular non-Hodgkin's lymphoma // Leukemia.—1998.— Vol. 12.—P. 1971-1976. 27. Neale G.A.M., Coustan-Smith E., Pan Q. et al. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood ALL // Ibid.—1999.— Vol. 13.—P. 1221-1226. 28. Offidani M., Olivieri A., MeleA. et al. High risk low-grade lymphoma: molecular remission after intensive sequential chemotherapy // Abstr. Amer. Soc. Hematol., 41sh ASH Annual Meeting.—New-Orlean, 1999.—N 5032. 29. Petter M.N, The significance of detection of minimal residual disease in childhood acute limphoblastic leukemia// Brit. J. Haematol.-1993.-Vol. 83.—P. 412. 30. Poirel H., Radford-WeissY., Rack K. etal. Detection of the chromosome 16 CBF(-MYH11 fusion transcript in myelomonocytic leukemias // Blood.—1995.— Vol. 85.-P. 1313-1322. 31. Preudomme Ñ. Good correlation between RT-PCR analysis of BCR-ABL transcript and relapse in 18 cases of Philadelphia (PH1) acute lymphoblastic leukemia // Abstr. Amer. Soc. Hematol. 38th Annual Meeting.— Orlando, 1996.—N 1899. 32. Privitera E., Rivolta A., Ronchetti ,D. et al. Reverse transcriptase / polymerase chain reaction follow-up and minimal residual disease detection in t(1;19)-positive acute lymphoblastic leukaemia // Brit. J. Haematol.-1996.-Vol. 92.-P. 653-658. 33. Roberts W.M. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia // New Engl. J. Med.-1997.-Vol. 336.-P. 317-323. .34. Roth M. Prognostic significance of Philadelphia chromosome-positive cells detected by the PCR after allogeneic bone marrow transplantation for chronic myelogenous leukaemia // Blood.-1992.-Vol. 79.— P.276-282. 35. Samaha H, Dumonlet C., Ketterer N. et al. Mantle cell lymphoma: a retrospective study of 121 cases // Leukemia.—1998.—Vol. 12.-P. 1281-1287. 36. Socie G., Clayuela J.M., Raynal B. et al. Influence of CD34 cell selection on the incidence of mixed chimaerism and MRD after allogenic unrelated donor transplantation//Ibid.—1998.-Vol. 12.—P.1440-1446. 37. Tobal Ê., Johnson P.R.E., Saunders M.J. et al. Detection of CBF(/MYH11 transcripts in patients with inversion and abnormalities of chromosome 16 at presentations and remission // Brit. J. Haematol.—1995.— Vol. 91.-P. 91-104. 38. Van Rhee F., Lin F., Cullis J.O. et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of haematologic relapse // Blood.— 1994.—Vol. 83.—P. 3377-3383. 39. Vasserman R. Residual disease at the end of the induc tion therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia // J. Clin. Oncol.-1992.-Vol. 102.-P. 1879-1888. 40. Verschraegen C.F. Quantification of the breakpoint cluster region rearrengement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia// Blood.-1995.-Vol. 85.-P. 2705-27Èñòî÷íèê: Íîâèê À.À. è äð. Âîïðîñû îíêîëîãèè. 2001. Ò.47. ¹3. Ñ.270-277